Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy

Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments

Avid Bioservices to Participate at Upcoming Investor Conferences

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021

Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments

Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021

Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)

Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock